***To the Editor,***

Acute pyelonephritis (APN) is a common infection of the kidney and renal pelvis in women but can progress to septic shock and multiple organ failure. In general, patients with mild APN who are able to take oral medication can be treated with oral antibiotics on an outpatient basis \[[@b1-kjim-2015-403]\]. Recent American and European guidelines recommend hospitalization for patients with APN who are sufficiently ill (high fever, high white blood cell count, vomiting, dehydration, or evidence of sepsis). Traditionally, medical literature on the antimicrobial resistance, treatment, and outcomes of APN has focused on patients who are hospitalized with APN. Data on the epidemiology and clinical outcomes of APN patients discharged from the emergency department (ED) and subsequently treated on an outpatient basis are scarce. Therefore, we conducted this study to characterize the clinical characteristics and outcomes of APN patients discharged from the ED (outpatient treatment group) and to compare them with APN patients hospitalized from the ED (hospitalization group).

This observational cohort study was performed at six hospitals in South Korea. We prospectively identified women aged \> 18 years whose urine culture was performed in the ED and grew bacteria by screening the microbiology laboratory database daily at each hospital from June 29 to October 11, 2014. Polymicrobial cases were excluded and for each patient, only the first episode of APN \[[@b2-kjim-2015-403]\] occurring during the study period was included. After reviewing the medical records, patients who had APN were enrolled in the study.

The subjects were followed up through each hospital's medical record system until hospital discharge or first outpatient follow-up visit. For the hospitalization group, treatment outcomes were assessed after 72 hours of treatment (early clinical success), and, if available, within 7 to 14 days after completion of antimicrobial therapy (final clinical cure). Clinical success was defined as resolution of fever and improvement of urinary tract symptoms or signs. For the outpatient treatment group, outcomes were evaluated at the time of first follow-up visit.

Of the 297 eligible women with APN who presented to the ED, two were excluded during the study period, because of immediate transfer to other hospitals. Of the remaining 295 patients who were included, 80 (27.1%) were discharged from the ED and 215 (72.9%) were hospitalized ([Table 1](#t1-kjim-2015-403){ref-type="table"}). The admission rates ranged from 54.9% to 92.1% in the six hospitals.

Compared with the hospitalization group, the outpatient treatment group was more likely to be younger (median age, 52 years vs. 65 years, *p* \< 0.001). These patients had less comorbidity, including cardiovascular diseases and diabetes mellitus. Previous hospitalization (5.0% vs. 15.3%, *p* = 0.017) and antibiotic use (3.8% vs. 12.6%, *p* = 0.026) before the first episode of APN during the study period were less commonly found in the outpatient treatment group. Further, the outpatient group more commonly presented with short median duration of fever (1 days vs. 2 days, *p* = 0.007) and typical lower urinary tract symptoms (for example, frequency in 61.3% vs. 36.7%, *p* \< 0.001). This group also less commonly had hypotension (2.5% vs. 11.2%, *p* = 0.02) and altered mental status (5.0% vs. 25.1%, *p* \< 0.001). Moreover, concurrent bacteremia was less common in the outpatient treatment group than in the hospitalization group (23.1% vs. 34.1%, *p* = 0.126), although the difference was not statistically significant. Complicated episodes were less commonly found in the outpatient treatment group. However, the distribution of etiology was similar in both groups: enteric Gram-negative bacteria, particularly Escherichia coli, was the most frequent cause of APN. Extended-spectrum β-lactamase (ESBL)-producing gram-negative bacteria were less commonly the causative organisms in the outpatient treatment group than in the hospitalization group, although the difference was not statistically significant (11.7% vs. 19.2%, *p* = 0.138).

Of the 80 patients in the outpatient treatment group, 61 were present for evaluation of clinical response at the first follow-up visit ([Fig. 1](#f1-kjim-2015-403){ref-type="fig"}). Among the 61 patients, 55 (90.2%) showed clinical success at the first outpatient follow-up. In contrast, in the hospitalization group, early clinical success at 72 hours after empiric antibiotic therapy was observed in 183 patients (85.1%). There was no significant difference in the clinical success between the two groups at the first assessment (*p* = 0.313), although the outcomes were not evaluated at the same follow-up time because of the natural limitation in the outpatient treatment group. Of 222 patients receiving appropriate empiric antibiotic therapy, 48 (92.3%) of 52 discharged patients showed clinical success at the first outpatient visit and 150 (88.2%) of 170 hospitalized patients showed early clinical success (*p* = 0.607). Of the 215 patients in the hospitalization group, final clinical cure was achieved in 163 (96.4%) of 169 patients. Four patients (1.9%) died in the hospital, two patients died due to APN 1 and 3 days after admission, one patient died of pneumonia 15 days after admission, and one patient died of heart failure 74 days after admission.

Nine (14.8%) of the 61 discharged patients received inappropriate empiric antibiotic therapy on discharge from the ED ([Table 2](#t2-kjim-2015-403){ref-type="table"}). The causative bacteria included *E. coli* in eight patients and *Proteus mirabilis* in one patient. Of those nine isolates, six were ESBL producers. The rate of clinical success at the first outpatient visit was lower in patients who received inappropriate empiric antibiotic therapy than in those who received appropriate empiric antibiotic therapy, but the difference was not statistically significant (77.8% vs. 92.3%, *p* = 0.212). Two (22.2%) of the nine patients receiving inappropriate empiric antibiotic therapy were admitted after the first outpatient visit as was the case with three (5.8%) of the 52 patients receiving appropriate therapy, although these differences were not statistically significant (*p* = 0.154). The two cases that received inappropriate empiric antibiotic therapy and admitted after the first outpatient visit were caused by ESBL producers.

The results of this study presented an overview of the clinical characteristics, microbiology, and short-term treatment outcomes of adult women with APN who were discharged from the ED. The overall admission rate in adult women with APN presenting to the ED was high (72.4%) in this study; this rate is higher than that reported in a previous study in Korea \[[@b3-kjim-2015-403]\]. Admission rates in patients with APN presenting to the ED vary widely depending on the country. In the Netherlands, 86% of adults with APN were hospitalized, while 26.9% of patients with APN in USA were hospitalized. To date, there has been no guideline or policy for admission of patients with APN in Korea, and the decision for admission is often subject to the physician's judgment. However, the admission rate for APN via the ED can be controlled or reduced: it decreased from 47.7% to 15.1% without complications after implementation of a standardized protocol for women with APN presenting to the ED \[[@b3-kjim-2015-403]\].

In this study, as expected, the outpatient treatment group had milder APN than the hospitalization group. Significantly, this outpatient treatment group was less commonly exposed to known healthcare-associated risk factors for antimicrobial resistance, due to which ESBL producers were less commonly the causative organisms in this outpatient treatment group. These findings reflect slightly better outcomes in terms of clinical success and admission at the first outpatient visit in the outpatient treatment group, although the differences were not statistically significant.

In the outpatient treatment group, patients receiving inappropriate empiric antibiotic therapy had a lower clinical success rate at the first follow-up and a higher admission rate after the first outpatient visit, although the differences were not statistically significant. It is known that inappropriate empiric antibiotic therapy leads to worse early clinical response and longer hospital stay than appropriate therapy in bacteremic APN, although this therapy does not affect the mortality or clinical cure rate \[[@b4-kjim-2015-403]\]. Interestingly, in this study, clinical failure and decision of admission at the time of first outpatient visit occurred only in patients whose condition was caused by ESBL producers. These findings are partly consistent with the findings of previous studies showing that inappropriate empiric antibiotic therapy for APN caused by ESBL-producing *E. coli* can delay recovery and result in longer hospitalization \[[@b5-kjim-2015-403]\]. Recently, in Korea, third-generation cephalosporin-resistant uropathogens have been increasingly detected in women with community-associated APN, even without healthcare-associated factors \[[@b2-kjim-2015-403]\].

Despite our important findings, this study has some limitations. First, we included only culture-proven cases, which might have led to an over- or under-estimation of the admission rate. Second, no information was available regarding the long-term results of the outpatient treatment group, and therefore, we were unable to directly compare the long-term outcomes (for example, final clinical success) between the outpatient treatment and hospitalization groups.

In conclusion, of adult women with APN presenting to the ED, the outpatient treatment group who were younger, had fewer comorbidities, and were less exposed to healthcare-associated factors were more likely to have mild infection. These patients can safely be treated on an outpatient basis without hospitalization; however, inappropriate empiric antibiotic therapy may delay recovery and hospitalization. Therefore, for optimal empiric antibiotic therapy, clinicians should always be vigilant to identify known risk factors for antimicrobial resistance before selecting empiric antibiotics for patients with APN presenting to the ED.
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###### 

Clinical characteristics between outpatient treatment and hospitalization groups

  Characteristic                                                        Women with APN in emergency department   *p* value^[a](#tfn2-kjim-2015-403){ref-type="table-fn"}^   
  --------------------------------------------------------------------- ---------------------------------------- ---------------------------------------------------------- ----------
  Age, yr                                                               52 (19-93)                               65 (19-94)                                                 \< 0.001
  Presence of comorbidity                                               36 (45.0)                                155 (72.1)                                                 \< 0.001
   Cardiovascular diseases                                              22 (27.5)                                89 (41.4)                                                  0.029
   Diabetes mellitus                                                    16 (20.0)                                73 (34.0)                                                  0.020
   Neurologic diseases                                                  7 (8.8)                                  38 (17.7)                                                  0.058
  Presence of underlying condition                                      11 (13.8)                                63 (29.3)                                                  0.006
   Admission within the preceding 90 days                               4 (5.0)                                  33 (15.3)                                                  0.017
   Use of antibiotics within the preceding 90 days                      3 (3.8)                                  27 (12.6)                                                  0.026
   Bed-ridden state                                                     1 (1.3)                                  23 (10.7)                                                  0.008
  Complicated UTI                                                       6 (7.5)                                  55 (25.6)                                                  0.001
  Healthcare-associated UTI                                             15 (18.8)                                53 (24.7)                                                  0.285
  Recurrent                                                             4 (5.0)                                  25 (11.6)                                                  0.089
  Clinical features at presentation                                                                                                                                         
   Duration of fever, day                                               1 (0-14)                                 2 (0-14)                                                   0.007
   Chill                                                                50 (62.5)                                158 (73.5)                                                 0.066
   Dysuria                                                              36 (45.0)                                80 (37.2)                                                  0.223
   Frequency                                                            49 (61.3)                                79 (36.7)                                                  \< 0.001
   Urgency                                                              10 (12.5)                                29 (13.5)                                                  0.824
   Suprapubic or perineal pain                                          20 (25.0)                                38 (17.7)                                                  0.159
   Flank pain                                                           27 (33.8)                                89 (41.4)                                                  0.232
   Anorexia, nausea, or vomiting                                        24 (30.0)                                98 (45.6)                                                  0.016
   Tenderness on costovertebral angle                                   66 (82.5)                                156 (72.6)                                                 0.079
   Altered mental status                                                4 (5.0)                                  54 (25.1)                                                  \< 0.001
   Systolic blood pressure \< 90 mmHg                                   2 (2.5)                                  24 (11.2)                                                  0.020
   Heart rate \> 90 beats/min                                           32 (40.0)                                121 (56.3)                                                 0.013
   Respiratory rate \> 20 breaths/min                                   23 (28.7)                                47 (21.9)                                                  0.216
   Temperature \> 38°C or \< 36°C                                       48 (60.0)                                157 (73.0)                                                 0.031
  Laboratory findings at presentation                                                                                                                                       
   WBC \> 12,000 or \< 4,000/pL or band form \> 10%                     26 (32.5)                                116 (54.0)                                                 0.001
   Platelet \< 150,000/pL                                               9 (11.4)                                 52 (24.2)                                                  0.016
   BUN \> 20 mg/dL or creatinine \> 1.5 mg/dL                           18 (22.5)                                89 (41.4)                                                  0.004
  SIRS criteria of ≥ 2^[b](#tfn3-kjim-2015-403){ref-type="table-fn"}^   42 (52.5)                                154 (71.6)                                                 0.002
  Uropathogen                                                                                                                                                               0.078
   *Escherichia coli*                                                   73 (91.3)                                183 (85.1)                                                 
   *Klebsiella pneumoniae*                                              1 (1.3)                                  12 (5.6)                                                   
   *Proteus mirabilis*                                                  2 (2.4)                                  7 (3.3)                                                    
   Enterococci                                                          0                                        3 (1.4)                                                    
   *Staphylococcus saprophyticus*                                       2 (2.5)                                  0                                                          
   Others^[c](#tfn4-kjim-2015-403){ref-type="table-fn"}^                2 (2.5)                                  10 (4.7)                                                   
   ESBL production                                                      9/77 (11.7)                              38/198 (19.2)                                              0.138
  Concurrent bacteremia                                                 12/52 (23.1)                             71/208 (34.1)                                              0.126

Values are presented as median (range) or number (%).

APN, acute pyelonephritis; UTI, urinary tract infection; WBC, white blood cell count; BUN, blood urea nitrogen; SIRS, systemic inflammatory response syndrome; ESBL, extended-spectrum β-lactamase.

Mann-Whitney, chi-square, or Fisher exact tests as appropriate.

Two or more of the following criteria: (1) heart rate \> 90 beats/min, (2) respiratory rate \> 20 breaths/min, (3) temperature \> 38℃ or \< 36℃ or (4) white blood cell \> 12,000/μL, \< 4,000/μL, or band form \> 10%

Others included *Acinetobacter baumannii*, *Citrobacter freundii*, *Enterobacter aerogenes*, Gram-positive rod, *Klebsiella oxytoca*, *Providencia rettgeri*, *Pseudomonas aeruginosa*, *Pseudomonas fluorescens*, *Serratia fonticola*, *Streptococcus agalactiae*, and *Streptococcus salivarius*.

###### 

Outcomes according to appropriateness of empiric antibiotic therapy in the outpatient treatment group

  Outcome                                                     Empiric antibiotic therapy   *p* value   
  ----------------------------------------------------------- ---------------------------- ----------- ------------------------------------------------------
  Interval from ED discharge to first outpatient visit, day   4 (1-8)                      3 (1-5)     0.157^[a](#tfn6-kjim-2015-403){ref-type="table-fn"}^
  Clinical success at first outpatient visit                  48 (92.3)                    7 (77.8)    0.212^[b](#tfn7-kjim-2015-403){ref-type="table-fn"}^
  Admission after first outpatient visit                      3 (5.8)                      2 (22.2)    0.154^[b](#tfn7-kjim-2015-403){ref-type="table-fn"}^

Values are presented as median (range) or number (%).

ED, emergency department.

Mann-Whitney test.

Fisher exact test.

[^1]: Current affiliation: Healthcare Review and Assessment Committee, Health Insurance Review & Assessment Service, Seoul, Korea
